NASDAQ: MMEDMinimed Group Inc Stock
$12.92-0.28 (-2.12%)
Updated Apr 27, 2026
MMED Price
$12.92
Fair Value Price
N/A
Market Cap
$3.63B
52 Week Low
$12.77
52 Week High
$20.48
P/E
N/A
P/B
1.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
N/A
Beta
1.94
Next Earnings
Jun 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MMED Overview
MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets, software platforms, and related accessories that help patients and healthcare providers effectively monitor and control blood glucose levels. The company was founded by Alfred E. Mann in 1983 and is headquartered in Northridge, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MMED's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
MMED
Ranked#26 of 45
Ranked#26 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.41 | A | |
| $3.26 | B | |
| $48.57 | B |
Be the first to know about important MMED news, forecast changes, insider trades & much more!
MMED News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MMED scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MMED is good value based on its book value relative to its share price (1.05x), compared to the US Health Information Services industry average (2.98x)
P/B vs Industry Valuation
MMED's short-term assets ($1.11B) exceed its short-term liabilities ($696.00M)
Short-term Liabilities Financials
MMED's short-term assets ($1.11B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MMED due diligence checks available for Premium users.
Valuation
MMED fair value
Fair Value of MMED stock based on Discounted Cash Flow (DCF)
Price
$12.92
Fair Value
$47.74
Undervalued by
72.94%
MMED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.05x
Industry
2.98x
MMED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MMED's financial health
Profit margin
Revenue
$790.0M
Net Income
-$119.0M
Profit Margin
-15.1%
Assets to liabilities
Assets
$4.3B
Liabilities
$881.0M
Debt to equity
0.25
MMED's short-term assets ($1.11B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MMED's short-term assets ($1.11B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MMED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$66.0M
Investing
-$53.0M
Financing
-$11.0M
MMED vs Health Information Service Stocks
Minimed Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.